Clinical trials: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Leukemia, Myelodysplastic Syndromes
Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00053287
- Testing
- carboplatin, fludarabine phosphate, thalidomide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma, Acute Myeloid Leukemia
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT03465540
- Testing
- AMG 397, Dexamethasone, Azacitidine
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 24 people
- Sponsor
- Amgen
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment…
- Trial name
- NCT03629171
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine, Venetoclax
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
The investigators hypothesize that CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) hematopoietic stem cells…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
- Trial name
- NCT02995655
- Testing
- CX-01, Azacitidine, Bone marrow biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or elderly patients with…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04746235
- Testing
- Decitabine and Cedazuridine, Venetoclax
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Gentulizumab Injection is an anti-CD47 monoclonal antibody. As a member of the immunoglobulin superfamily, CD47 is expressed at low levels on many cells of the body, including hematopoietic cells (red blood cells, lymphocytes…
- Trial name
- NCT05263271
- Testing
- Gentulizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with…
- Trial name
- NCT06419634
- Testing
- BMS-986497, Azacitidine, Venetoclax
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, B-Cell, T-Cell Lymphoma
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with hematologic malignancies.
- Trial name
- PI3K (NCT02017613)
- Testing
- RP6530
- Where
- 3 sites in France, Italy
- Volunteers
- 35 people
- Sponsor
- Rhizen Pharmaceuticals SA
AML, MDS
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients.
- Trial name
- DEPLETHINK (NCT03466320)
- Testing
- NKR-2
- Where
- 7 sites in United States, Belgium
- Volunteers
- 21 people
- Sponsor
- Celyad Oncology SA
Leukemia, Myeloid, Acute
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this research study is to look at overall health status and how acute myeloid leukemia (AML) responds to a stem cell transplant when followed with cyclophosphamide.
- Trial name
- NCT02057770
- Testing
- busulfan, fludarabine phosphate, total-body irradiation (TBI)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndromes
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
This is a first-in-human dose escalation/dose expansion study to evaluate the safety and identify the best dose of modified immune cells, PRGN-3006 (autologous chimeric antigen receptor (CAR) T cells), in adult patients with…
- Trial name
- NCT03927261
- Testing
- PRGN-3006 T Cells
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Precigen, Inc
Acute Myeloid Leukemia
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.
- Trial name
- NCT01034410
- Testing
- AS1411, Cytarabine
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- Antisoma Research
Relapsed and/or Refractory CD33+ AML
Allogeneic CART-33 for Relapsed/Refractory CD33+ AML
The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 33 (CD33)-directed chimeric antigen receptor modified T cells (CART-33) infusions in patients with relapsed / refractory…
- Trial name
- NCT02799680
- Testing
- allogeneic CART-33
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Leukemia, Myeloid, Acute
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
This is a research study to be done at multiple sites in participants with advanced acute myeloid leukemia (AML) that have a mutation in Fms-like tyrosine kinase-3 internal tandem duplications (FLT3-ITD).
- Trial name
- NCT04209725
- Testing
- CPX-351, Quizartinib
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- SCRI Development Innovations, LLC
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
This study was designed as a prospective, multicenter, open-label, randomized controlled trial. Eligible participants were patients aged 15-60 years with high-risk or relapsed/refractory acute myeloid leukemia (AML), acute…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
- Trial name
- NCT07562568
- Testing
- SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Chronic Myeloproliferative Disorders, Leukemia
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006379
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myeloid Leukemia
A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Clifutinib Besylate in Relapsed/refractory AML patients with FLT3-ITD mutation.
- Trial name
- NCT04827069
- Testing
- Clifutinib Besylate
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
Acute myeloid leukemia (AML) is one of the most common hematologic malignancies. With increasing life expectancy and the aging of society, the incidence of AML in the elderly population is rising.
- Trial name
- NCT07500753
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Relapsed/Refractory Acute Myeloid Leukemia
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The goal of this expanded access program is to provide rapid access to magrolimab free-of-cost material, to treat patients in the United States suffering from relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT05627466
- Testing
- Magrolimab
- Sponsor
- Gilead Sciences